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E-mail: karlheinz.peter@baker.edu.auAbdominal aortic aneurysm (AAA) is an often deadly disease
without medical, non-invasive treatment options. The upre-
gulation of vascular cell adhesion molecule-1 (VCAM-1) on
aortic endothelium provides an early target epitope for a novel
biotechnological theranostic approach. MicroRNA-126 was
used as a therapeutic agent, based on its capability to down-
regulate VCAM-1 expression in endothelial cells and thereby
reduces leukocyte adhesion and exerts anti-inflammatory
effects. Ultrasound microbubbles were chosen as carriers,
allowing both molecular imaging as well as targeted therapy
of AAA. Microbubbles were coupled with a VCAM-1-targeted
single-chain antibody (scFvmVCAM-1) and a microRNA-126
mimic (M126) constituting theranostic microbubbles
(TargMB-M126). Targ
MB-M126 downregulates VCAM-1 expres-
sion in vitro and in an in vivo acute inflammatory murine
model. Most importantly, using TargMB-M126 and ultra-
sound-guided burst delivery of M126, the development of
AAA in an angiotensin-II-induced mouse model can be
prevented. Overall, we describe a unique biotechnological
theranostic approach with the potential for early diagnosis
and long-sought-after medical therapy of AAA.
INTRODUCTION
Abdominal aortic aneurysm (AAA) presents a major cause of sudden,
premature death.1 Patients diagnosed with AAA are typically moni-
tored by regular ultrasound scans. If the diameter of the aorta has
reached 5.5 cm, the only effective treatment is surgical or endovascu-
lar repair, which is associated with a substantial complication rate.2
Despite several clinical trials testing various treatment options, there
are currently no secondary prevention measures or non-invasive
treatment options available.2
We propose and describe here a novel theranostic approach for
early diagnosis and a long-sought-after treatment option for AAA.
It combines the use of recombinant antibody-targeted ultrasound
microbubbles (MBs) for imaging and ultrasound-burst selective
drug delivery, microRNA (miR)-based nucleic acid therapeutics,
and the utilization of an endothelial surface protein both as target-
ing epitope as well as effector molecule for anti-inflammatory
therapy.1056 Molecular Therapy Vol. 26 No 4 April 2018 ª 2018 The Authors.
This is an open access article under the CC BY-NC-ND license (htVascular cell adhesion molecule-1 (VCAM-1) is an endothelial
adhesion molecule that mediates leukocyte adhesion to inflamed
endothelial cells (ECs) and is upregulated in vascular diseases,
such as atherosclerosis3 and AAA.4 VCAM-1 expression has been
shown to be regulated by miR-126, which thereby modulates
vascular inflammation and integrity.5–8 miRs have attracted major
interest as therapeutic agents and are currently being tested in
multiple clinical trials.9 We investigated a miR-126 mimetic
(M126) as a therapeutic approach to downregulate VCAM-1 expres-
sion and ultimately to deliver anti-inflammatory therapy to the area
of AAA development.
For AAA diagnosis/imaging, ultrasound is ideal as it is highly mobile,
has no side effects, and provides real-time imaging and overall is high-
ly cost-effective. MBs are US Food and Drug Administration (FDA)
approved as ultrasound contrast agents and can be used as drug car-
riers, allowing localized delivery of drugs upon the selective delivery
of an ultrasound burst. We have previously shown that MBs can be
used for theranostic approaches, e.g., by conjugation with activated
platelet-targeted antibodies and fibrinolytic drugs, allowing simulta-
neous diagnosis and treatment of acute thrombosis.10,11
Undoubtedly, identifying targets for AAA treatment that non-
invasively impede upon aneurysmal growth is of great clinical
relevance and has inspired recent novel studies.12 Our approach spe-
cifically and non-invasively targets inflamed ECs via a single-chain
antibody (scFv) toward VCAM-1. In addition to this scFv-based
targeting, ultrasonic bursting provides additional selectivity for
transfection of miR-126 mimetics. This unique, dual-targetedtp://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation and Functional Evaluation of
scFvmVCAM-1, miR-126 Constructs, and Targ
MB
(A) Gene map of scFvmVCAM-1 construct in pAC6 vector.
(B) Electrophoresis of pAC6 plasmid (above 3 kB
marker) after restriction digest is shown; successful
enzymatic digestion is observed with visualization of
1-kB cut out. (C) Electrophoresis of scFvmVCAM-1 (around
1 kB marker) after PCR amplification is shown. (D and E)
Western blot analysis (D) shows successful protein pu-
rification of scFvmVCAM-1 demonstrated with horseradish
peroxidase (HRP)-coupled anti-6 His-tag antibody,
and in vivo biotinylation of scFvmVCAM-1 (E) demonstrated
with streptavidin-HRP; both western blots show bands
around 33 kDa. (F) Functionality of scFvmVCAM-1 and
efficiency of in vivo biotinylation were evaluated with
R-phycoerythrin streptavidin via flow cytometry; speci-
ficity of scFvmVCAM-1 (5 mg/mL)-targeting VCAM-1 was
demonstrated in a competitive assay, using commer-
cially available CD106 and scFvmVCAM-1 (n = 3). (G) Flow
cytometry assays evaluated effect of miR-126 con-
structs on VCAM-1 expression; assays demonstrate
increased VCAM-1 expression on SVEC4-10 cells after
transfection with A126 and decreased expression with
M126 as compared to those with S126 (n = 3). Repre-
sentative flow cytometry dot plots are shown below each
bar graph. (H) Representative images show successful
transfection of miR-126 using TargMB via microscopy
using bright field and TRITC fluorescence channel; scale
bar = 10 mm. (I) Flow cytometry analysis detected Cy3
(on miR) after transfection into SVEC4-10 cells (n = 9).
(J) Flow cytometry assays show no change in VCAM-1
expression when non-TargMB was used for transfection
of miR-126. (K) Flow cytometry assays show decreased
expression of VCAM-1 after transfection with TargMB-
M126 as compared to Targ
MB-A126 (n = 5); assays with
two groups were analyzed using Student’s t tests and
those with more than two groups with equal numbers
using repeated-measures one-way ANOVA with Bon-
ferroni post tests.
www.moleculartherapy.orgdelivery system is well suited to provide a high therapeutic payload
directly to the site of inflamed endothelium at the AAA.
Overall, the presented combination of molecular imaging of AAA and
targeted drug delivery approach holds immense potential for clinical
translation in a disease with limited therapeutic options and often
fatal outcome.
RESULTS AND DISCUSSION
To allow targeting of MBs, a single-chain antibody targeting mouse
VCAM-1 (scFvmVCAM-1)
13 was adapted for MB conjugation by sub-
cloning into the pAC6 vector system, consisting of a C-terminal
AviTag, which enables in vivo biotinylation during protein production
(Figure 1A). DNA amplification and restriction digest were evaluated
by electrophoresis (Figures 1B and 1C), and production of the adaptedscFvmVCAM-1 was confirmed by western blotting (Figures 1D and 1E).
The non-binding control (scFvMut) was generated previously.
14
Mouse VCAM-1-expressing Mus musculus axillary lymph node/
vascular epithelium (SVEC4-10) cells were used to confirm the bind-
ing specificity of scFvmVCAM-1. Binding of commercially available
anti-CD106 together with a goat-anti-rat-fluorescein-isothiocyanate
(GAR-FITC) secondary antibody confirmed VCAM-1 expression
on SVEC4-10 cells, whereas no binding was observed for the isotype
FITC control or GAR-FITC secondary antibody (Figure S1A).
Fluorescence intensity in the SVEC4-10 cells was increased using
biotinylated scFvmVCAM-1 with R-phycoerythrin (PE) streptavidin
as compared to controls (Figure 1F). Competitive binding between
anti-CD106 and scFvmVCAM-1 confirmed the specificity of
scFvmVCAM-1 (Figure 1F).Molecular Therapy Vol. 26 No 4 April 2018 1057
Molecular TherapyThree different cholesterol- (for attachment to MBs and transfer
through the cell membrane) and fluorescence-tagged miR-126
oligos were used: (1) anti-miR-126 (A126), which induces VCAM-1
expression; (2) mimic-miR-126 (M126), which represses VCAM-1
expression; and (3) scrambled-miR-126 (S126) as control. Changes
in VCAM-1 expression were assessed after the respective transfection
into SVEC4-10 cells using qRT-PCR and flow cytometry. We
observed increased VCAM-1 expression using A126 and decreased
expression with M126 as compared to S126 (Figure S1C). Similarly,
flow cytometry assays demonstrated significantly more VCAM-1
expression with A126-transfected SVEC4-10 cells and less with
M126, as compared to those with S126 (Figure 1G).
MBs were first conjugated with either scFvmVCAM-1 (Targ
MB) or
non-binding scFvMut (non-Targ
MB), followed by incubation with
the fluorescence-tagged miR therapeutics. The 30 cholesterol tag has
been proven to increase the binding capacity of the miRs to MBs15;
however, it is yet to be investigated how long these bonds are stable
in vivo in the presence of other hydrophilic blood components. For
additional selectivity of our miR therapeutics, we employed an ultra-
sonic drug delivery approach using ultrasound bursts. After incuba-
tion of TargMB-miR with SVEC4-10 cells and washing, we burst the
TargMB-miR to deliver the Cy3-tagged miR. Fluorescence was visible
in the nuclei of cells incubated with TargMB-miR, but not with the
non-TargMB-miR (Figures 1H and S1B). Similar results were demon-
strated on flow cytometry (Figure 1I).
Following the promising results of our dual-targeting and ultrasonic
drug delivery, we investigated whether the expression of VCAM-1 on
SVEC4-10 cells could be altered using this approach. Flow cytometry
results showed no alteration in VCAM-1 expression of SVEC4-10
cells post-transfection with non-TargMB-A126, non-Targ
MB-M126,
non-TargMB-S126, or non-Targ
MB alone as controls (Figure 1J).
Similarly, no differences in VCAM-1 expression were observed
post-transfection using just TargMB alone as control or TargMB-S126
(Figure 1K). However, a significant decrease in VCAM-1 expression
was seen in cells transfected using TargMB-M126 as compared to
TargMB-A126 (Figure 1K), demonstrating the specific targeting ability
of our scFvmVCAM-1 and successful ultrasonic drug delivery, which
resulted in successful modulation of VCAM-1 expression.
As a first in vivo proof of concept, we validated the efficiency and effec-
tiveness of our TargMB-M126 using a murinemodel of acute inflamma-
tion intraperitoneal (i.p.) injection of lipopolysaccharide (LPS). Mice
were then randomized before being treated with TargMB-M126,
TargMB-A126, or Targ
MB-S126. After 5 min, ultrasound bursts were
applied to the abdominal and thoracic aorta. Using qRT-PCR, we
observed decreased VCAM-1 gene expression of the thoracic aorta
in animals treated with TargMB-M126 and increased expression in
those treated with TargMB-A126 compared to Targ
MB-S126 (Figure 2B).
Immunohistochemistry using goat-anti-mouse VCAM-1 polyclonal
(GAM-VCAM-1) antibody also showed decreased VCAM-1 expres-
sion in animals treated with TargMB-M126 as compared to those
treated with TargMB-A126 or Targ
MB-S126 (Figure 2A).1058 Molecular Therapy Vol. 26 No 4 April 2018Following the promising results from the in vivo acute inflammation
model, we investigated our targeted theranostic approach for the
prevention/treatment of aneurysm severity in an angiotensin
(Ang)-II-induced AAAmurine model (Figure 2C). Ultrasoundmoni-
toring of the abdominal aorta showed an increase in the suprarenal
(pre-renal) diameter 1 week post-Ang-II induction for all treatment
groups and a slight increase in the infrarenal (post-renal) diameter,
as compared to baseline measurements (Figure S2). In order to deter-
mine the diagnostic capability of the TargMB on the abdominal aorta
wall, we measured the contrast intensity both before and 20 min post-
injection. A significant difference in contrast intensity was observed
in the Ang-II-induced AAA animals, 20 min after the injection of
TargMB, demonstrating that our unique VCAM-1-targeted MBs can
bind directly at the site of inflamed ECs where AAA develops (Fig-
ure 2D). No increase in contrast intensity was seen in healthy PBS
control mice (Figure 2E).
We then utilized our theranostic approach of TargMB loaded with
miRs to investigate the impact of TargMB-M126 upon aneurysm
severity. Weekly intravenous injection, ultrasound imaging, and
ultrasonic bursting (abdominal aorta, both suprarenal and infrarenal)
were performed. Ultrasound measurements of the abdominal aorta
4 weeks post-treatment showed a greater difference in vessel diameter
(compared to baseline before disease induction) for animals treated
with TargMB-A126 or Targ
MB-S126 as compared to those treated
with TargMB-M126 (Figures 2F and 2G). At week 4, 3D ultrasound
reconstruction of the abdominal aorta showed massive areas of pla-
que buildup and aneurysm in animals treated with TargMB-A126 or
TargMB-S126, but not in those treated with Targ
MB-M126 (Figure 3A;
Movies S1, S2, and S3). These results were further confirmed macro-
scopically on vessel isolation (Figure 3B). Furthermore, immunohis-
tochemistry using GAM-VCAM-1 antibody confirmed the decreased
VCAM-1 expression for animals treated with TargMB-M126 as
compared to those treated with TargMB-A126 or Targ
MB-S126 (Fig-
ure 3C). Martius Scarlet Blue (MSB) staining also showed plaque
buildup and aneurysm in the abdominal aortas of animals treated
with TargMB-A126 or Targ
MB-S126, whereas very little plaque buildup
was observed with TargMB-M126 (Figure 3D).
Ultrasound imaging for the anatomical diagnosis and monitoring of
AAA is well established in clinical practice. This study extends the
use of ultrasound in AAA toward a unique theranostic application,
which allows simultaneous diagnosis and therapy of AAA. We
demonstrate that MBs can be used as functional ultrasound contrast
agents to assess the inflammatory state of the endothelium, as well
as for targeted delivery of therapeutic anti-inflammatory drugs. The
targeted delivery of miRs is achieved by conjugating a scFv, which
specifically binds to mouse VCAM-1, onto MBs, thereby increasing
the therapeutic payload and allowing targeted drug delivery specif-
ically at the site of AAA. We cannot exclude the possibility that there
might be free cholesterol-tagged miRs present in the blood stream,
which could also be transferred into the cells within the area of disease,
potentially facilitated by the ultrasound destruction of our targeted
MBs. However, our study demonstrates that the anti-miR-126,
Figure 2. Demonstration of TargMB-miR Effect on
VCAM-1 Expression in Acute Inflammatory Murine
Model, TargMB Binding to Abdominal Aorta of
Ang-II-Induced AAA Animals, and Successful
Targeted Delivery of miR-126 to Site of Disease
(A) Representative images from immunohistochemistry
using goat-anti-mouse VCAM-1 polyclonal antibody show
decreased VCAM-1 expression for animals treated
with TargMB-M126 as compared to those treated with
TargMB-A126 or Targ
MB-S126 in LPS model of acute
inflammation; scale bar = 50 mm. (B) In the same model,
VCAM-1 expression on the thoracic aorta assessed via
qRT-PCR demonstrates decreased expression in animals
treated with TargMB-M126 and increased expression in
animals treated with TargMB-A126 (n = 3–4); for qRT-PCR
assays, ratio of gene expression for animals treated with
TargMB-S126 was set to 1. (C) Mechanism of action of
double-selective TargMB-miR therapy in AAA is shown.
(D and E) Increased contrast intensity on molecular ultra-
sound imaging demonstrates (D) successful binding of
TargMB to the inflamed abdominal aorta of mice with
Ang-II-induced AAA and (E) no change in healthy mice
used as a control (n = 3–6). Ultrasound analysis of the
abdominal aorta was measured 4 weeks post-treatment.
The difference in diameter (from the baseline before
disease induction) was calculated. (F and G) A significant
increase in the diameter of the (F) suprarenal and (G)
infrarenal abdominal aortawas observed in animals treated
with TargMB-A126 and Targ
MB-S126, whereas the diameter
of TargMB-M126 was preserved (n = 5 [S126], n = 9 [M126],
n = 8 [A126]). Assays with two groups were analyzed using
Student’s t tests, and those with more than two groups
using ordinary one-way ANOVAwith Bonferroni post tests.
www.moleculartherapy.orgTargMB-A126, increases VCAM-1 expression and further aggravates
AAA, whereas treatment with a mimic of miR-126, TargMB-M126,
downregulates VCAM-1 expression on the intraluminal surface of
the aneurysmal area and effectively prevents the development of
AAA. To the best of our knowledge, this is the first study to present
targeted theranostic MBs for the therapeutic delivery of miRs in an
AAA model. Our targeting approach is specific for areas with
VCAM-1 expression, thereby allowing the miR therapeutics to be
delivered directly to the area of interest. The use of molecular ultra-
sound technology to destroy theMBs bound to the wall of the inflamed
aorta and to release the miR therapeutics enhances the specificity ofMothis novel therapeutic approach. These data pro-
vide proof of concept for a novel, non-invasive,
and risk-free theranostic strategy (Figure S3)
that allows monitoring and holds great potential
to ultimately prevent aneurysmal growth of the
abdominal aorta.
We used scFvs for targeting of our MBs because
they have major advantages over traditional an-
tibodies. ScFvs are small antibody fragments
lacking the Fc region and therefore are mini-mally immunogenic.16 In addition, scFvs allow optimization via mo-
lecular biology methods, including fusion with drugs,14,17 as well as
incorporation of specific tags and sequences for purification, bio-
conjugation, and imaging.18 Our group has developed several highly
specific scFvs for diagnostic imaging,14,19–21 targeted therapy,17,22–24
and theranostic approaches.10
Pioneering studies have analyzed the circulating levels of vascular and
inflammation-associated miRs in atherosclerosis,25 acute myocardial
infarction,26 and AAA.27–29 In particular, one such miR that has been
found to be upregulated in AAA is the endothelium-relatedlecular Therapy Vol. 26 No 4 April 2018 1059
Figure 3. Representative Images of Three-Dimensional Ultrasound Reconstructions of Abdominal Aorta, Photographs of Vessel Isolations,
Immunohistochemistry, and Martius Scarlet Blue Demonstrate Profound Effect of VCAM-1-Targeted miR-Carrying Microbubbles
(A) 3D ultrasound reconstruction of abdominal aorta shows vessel lumen (in red), as well as massive areas of plaque buildup and aneurysm (in blue), from animals treated with
TargMB-A126 or Targ
MB-S126, but not in animals treated with Targ
MB-M126. (B) Vessel isolation shows clean abdominal aorta in mice treated with Targ
MB-M126 but plaque
buildup and aneurysms in mice given TargMB-S126 or Targ
MB-A126. (C) Immunohistochemistry confirmed a decrease in VCAM-1 expression for Targ
MB-M126-treated animals
as compared to those treated with TargMB-A126 or Targ
MB-S126. (D) Martius Scarlet Blue showed plaque buildup and aneurysm in abdominal arteries of Targ
MB-A126- or
TargMB-S126-treated animals, whereas very little plaque buildup was observed in Targ
MB-M126-treated mice.
Molecular TherapymiR-126.29 Therapeutic miR approaches have attracted major inter-
est, with both pre-clinical and clinical reports describing their
immense potential to regulate specific gene expression in a broad1060 Molecular Therapy Vol. 26 No 4 April 2018range of diseases.9 Several miR-based therapies have been assessed
in AAA, such as targeting miR-21, miR-29, miR-181, miR-205, and
miR-712.30–33 Within the setting of AAA, dysregulation of ECs
www.moleculartherapy.orgaugments localized inflammation and expression of integrins and
adhesion molecules on the endothelial luminal surface, consequently
increasing leukocyte attachment, rolling, and ultimately migration/
infiltration into the intimal layer.4,5,28 MiR-126 is understood to be
exclusive to ECs and therefore has been identified as a crucial endog-
enous mediator of vascular integrity and angiogenesis and regulator
of adhesion molecules.5–7 Our in vitro work also highlights the use
of M126 for the suppression of VCAM-1 expression, and the opposite
has been observed using A126.
A recent study provided compelling evidence of miR-126’s anti-
inflammatory effects via increased localized enrichment of CXCL12
following apoptotic microparticle blebbing from ECs, of which
miR-126 is a major constituent.34 This study also showed that miR-
126 therapy via delivery of endothelial apoptotic bodies decreased
overall atherosclerotic lesion size in mouse models of atheroscle-
rosis,34 further validating a role for miR-126 in disease models of
endothelial dysfunction and inflammation. Our acute inflammatory
model shows that targeted delivery of miR-126 can alter VCAM-1
expression on the thoracic and abdominal aorta of LPS-treated mice.
Based on the presented in vivo data, the clinical translation of our tar-
geted theranostic approach appears highly promising for patients
with AAA. The VCAM-1-targeting MBs enrich the miR therapeutics
at the site of activated ECs, and together with the localized application
of an ultrasound burst, non-specific uptake of miR therapeutics in
other cell types can be minimized. Overall, the presented theranostic
approach has the potential to provide a long-sought-after medical
treatment option for patients with AAA.
MATERIALS AND METHODS
Generation of Anti-mVCAM-1 Single-Chain Antibody Containing
an AviTag Motif at the C Terminus
The generation of the scFvmVCAM-1 has been described previously and
was a gift from Prof. Claudia Gottstein.13 The scFvmVCAM-1 was sub-
cloned into the pAC6 vector system (Avidity, Aurora, CO), which
consists of the AviTag motif at the C-terminal. PCR was performed
with a sense primer that anneals at the beginning of the scFv sequence
and an antisense primer that anneals directly to the 6His-tag region
at the end of the scFv. The following primers were used for PCR: sense
strand: 50–CAG CCG GCC ATG GCG CAG GTT CA–30 and anti-
sense strand: 50–TCA GAT CCC GGG TAA TGG TGA TGG TGA
TGA TG–30. The antisense strand includes the XmaI restriction
site. After amplification by PCR, the constructs were then digested
with the restriction enzymes NotI and XmaI (both New England
Biolabs, Ipswich, MA) and cloned into pAC6. Electrophoresis on a
0.8% agarose gel with SYBR Safe DNA gel stain (Invitrogen, Carlsbad,
CA) was utilized to analyze amplifications of DNA by PCR and
restriction digests. Ligation of the plasmids was performed with T4
ligase (NEB, Ipswich, MA) at 16C overnight. The resulting plasmid
constructs were then transformed into Turbo competent E. coli cells
(NEB, Ipswich, MA). The transformed cells were grown in Luria-
Bertani (LB) media containing 100 mg/mL ampicillin and 100 mM
glucose at 37C, and the plasmids were purified using a PlasmidMini-Prep Kit (QIAGEN, Hilden, Germany). The respective plasmids
were analyzed by electrophoresis on a 0.8% agarose gel with SYBR
green, and constructs were confirmed by DNA sequencing. The
DNA was then transformed into electrocompetent cell EVB101
(Avidity, Aurora, CO) by electroporation with Bio-Rad Gene Pulser.
All agarose gels were visualized using a Bio-Rad Gel-Doc system with
Quantity One software (Bio-Rad, Hercules, CA).
Expression, In Vivo Biotinylation, and Purification of
scFvmVCAM-1-AviTag Construct
Bacterial strains of E. coli harboring the plasmid pAC6-scFvmVCAM-1-
AviTag were used to inoculate 5 mL of trytone-HEPES-yeast (THY)
media containing 10 mg/mL chloramphenicol and 100 mg/mL ampi-
cillin at 37C.14 After culturing overnight, 5 mL of the overnight cul-
ture was transferred into 1 L of THY media containing 100 mg/mL
ampicillin in a non-baffled Erlenmeyer flask. Glucose was added to
the THY media to 0.5% final concentration. In vivo biotinylation
was induced by 50 mM Biotin-D, 50 mM bicine, and 1.5 mM isopro-
pyl b-D-thiogalactoside, when the optical density 600 (OD600) of the
culture reached 0.7 units. After 3 hr induction, the cells were spun
down and resuspended in BugBuster Master Mix (Novagen, Darm-
stadt, Germany). The cell debris was spun down, and the inclusion
bodies were used for protein extraction via 8 M urea. All purified sin-
gle-chain antibodies carry a 6His-tag at the C-terminal end of their
amino acid sequence for purification by immobilized metal affinity
chromatography (IMAC) or for fluorescence-activated cell sorting
(FACS) analysis. Proteins were purified with a nickel-based metal
affinity chromatography column, Ni-NTA column (Invitrogen,
Carlsbad, CA), according to the manufacturer’s instruction manual.
Fractions of 1 mL were collected and dialyzed against 6 M urea,
decreasing slowly in 2 M increments until PBS.
Evaluation of Purity and Efficiency of the In Vivo Biotinylation of
the scFvmVCAM-1-AviTag Construct
The purity of the proteins and the efficiency of in vivo biotinylation
were analyzed by western blotting. 30 mL of each purified protein
and 6 mL of 5 reducing SDS loading buffer were added to 1.5-mL
tubes and denatured at 96C for 5 min. The samples were run on
SDS-PAGE gel in SDS running buffer at 100 V for 2 hr. The gel
was then used for western blotting at 100 V for 1 hr 30min. Themem-
brane was blocked with 1% BSA and hybridized with a specific horse-
radish peroxidase (HRP). Anti-6His-tag antibody HRP was used to
detect the protein construct, and streptavidin-HRP (BD Biosciences,
San Jose, CA) was used to determine the success of the in vivo
biotinylation of the protein construct. Secondary hybridization was
performed with SuperSignal West Pico chemiluminescent substrate
(Thermo Scientific, Waltham, MA), an enhanced chemiluminescent
(ECL) substrate for the HRP enzyme.
Cholesterol-Tagged miRNA
The sequences of the miR-126 are as follows: mimic-miR-126 (M126)
50–UCG UAC CGU GAG UAA UAA UGC G–30; anti-miR-126
(A126) 50–CGC ATT ATT ACT CAC GGT ACG A–30; and
scramble-miR-126 (S126) 50–CGC UCA UUC UGC CGG UUGMolecular Therapy Vol. 26 No 4 April 2018 1061
Molecular TherapyUUA UG–30. All miRs were modified with 2-O-methyl, 50-Cy3, and
30-cholesterol (VBC Biotech Services, Vienna, Austria).
mVCAM-Expressing SVEC4-10 Cell Culture
SVEC4-10 mice endothelial cells (ATCC, Manassas, VA) were
cultured in DMEM (Invitrogen, Carlsbad, CA), supplemented with
1% penicillin/streptomycin, 1% L-glutamine (200 mM), and 10% fetal
calf serum to the media (Gibco,Waltham, MA).When the monolayer
adherent SVEC4-10 cells reached confluency of 90%, a dissociation
reagent containing 0.05% trypsin-EDTA (Gibco, Waltham, MA)
was used to detach the cells into a suspension.
Flow Cytometry
SVEC4-10 cells were incubated with 10 mg/mL of purified
scFvmVCAM-1 for 10 min at 37C followed by Penta-His AlexaFluor
488 conjugate (QIAGEN, Hilden, Germany) or R-phycoerythrin
streptavidin (Jackson ImmunoResearch Laboratories, West Grove,
PA) for 15 min. As a positive control and to determine the VCAM
expression, the cells were incubated with CD106 (anti-VCAM) rat-
anti-mouse antibody for 10 min at 37C followed by a goat-anti-rat
FITC (GAR-FITC) secondary antibody for 15 min. Samples were
fixed with 1 Cellfix (BD Biosciences, San Jose, CA) and analyzed
by FACS Calibur (BD Biosciences, San Jose, CA). The cell population
was distinguished using the forward and sideward light scatter profile.
A gate was set around the cell population, and 10,000 cells were
analyzed. For determination of VCAM-1 expression, single staining
using CD106 and GAR-FITC secondary antibody was used. For
determination of miR-126 transfection, the Cy3 on the 50 of the oligo
was used.
qPCR for Gene Expression
For in vitro work, the total RNA was extracted using Trizol reagent
(Invitrogen, Carlsbad, CA) under RNase-free conditions. A DNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA)
was used to obtain cDNA from the total RNA samples, according
to the manufacturer’s instructions. qRT-PCR of miR was carried
out using a TaqMan Reverse Transcription Kit (Applied Biosystems,
Foster City, CA), according to the manufacturer’s instructions. For
in vivo work, total RNA was extracted using a fibrous tissue isolation
kit (QIAGEN, Hilden, Germany) under RNase-free conditions as per
the manufacturer’s instructions. Initially, two-step qRT-PCRwas per-
formed using identical reagents as mentioned previously; however,
low yields of RNA on account of the small sample size of the thoracic
aorta led to the use of a one-step QuantiFast SYBR green qRT-PCR kit
(QIAGEN, Hilden, Germany) for all further assays. All samples
were performed in triplicate. The expression levels of VCAM-1
were calculated by the delta-delta Ct method using GAPDH as an
internal control.
Preparation of Microbubbles
VisualSonics Target-Ready MBs (8.4  108 MBs; VisualSonics,
Toronto,Canada)were resuspended in 1mL sterile saline (0.9% sodium
chloride) according to the manufacturer’s instructions. 20 mg of
scFvmVCAM-1 or a non-binding scFvMut were added to each milliliter1062 Molecular Therapy Vol. 26 No 4 April 2018of MBs to generate TargMB or non-TargMB as control, respectively,
and incubated at room temperature for 20 min. The average radius of
a MB is around 1.5 mm, and MBs bear an average of 7,600 streptavidin
molecules per mm2 MB surface, resulting in approximately 6,000
biotinylated scFvmolecules per mm2 of theMB. TargMB or non-TargMB
was incubated with 100 mg/mL of one of the three cholesterol-tagged
miRs: M126; A126; or S126. This creates 1 molecule of cholesterol-miR
to every 200 lipids on the MBs. The following terms are used for this
manuscript: TargMB-M126 (VCAM-1-targeted MBs with mimic-
miR-126); TargMB-A126 (VCAM-1-targeted MBs with anti-miR-126);
and TargMB-S126 (VCAM-1-targeted MBs with scramble-miR-126).
For in vitro experiments, 10 mL of MB, containing 0.2 mg of scFv and
100 ng of miR, were used. For in vivo experiments, 100 mL of MB,
containing 2 mg of scFv and 10 mg of miR, were given to each animal
per injection.
Ultrasound Burst for Targeted Transfection of miR-126 Using
VCAM-1-Targeted Microbubbles Loaded with miR-126
SVEC4-10 cells were seeded into 35  10 mm Petri dishes (Sarstedt,
Neumbrecht, Germany) and incubated to allow attachment over-
night. Petri dishes were carefully filled with PBS with calcium and
magnesium to the brim and taped shut using Parafilm M (Bemis,
Neenah, WI). The TargMB-M126, Targ
MB-A126, or Targ
MB-S126 was
injected using a 30 G needle into the Petri dishes through the Parafilm
M. The Petri dishes were placed with the bottom facing up and were
gently shaken for 5min. A washing step was performed to remove un-
bound MBs before ultrasound bursting was employed to destroy the
bound MBs and enable the miR to enter the cells. For washing, the
Parafilm M was removed, the supernatant was discarded, and fresh
media were added. Ultrasound was performed on the cells using color
Doppler mode for 30 s per field of view (4 fields of view per Petri dish)
to destroy the MBs. Cells were incubated for 48 hr before microscopy.
In Vivo Mouse Experiments
Male C57BL/6 mice or apolipoprotein E knockout (Apo E/) mice
were obtained from the Alfred Medical Research and Education
Precinct Animal Services and assigned randomly to one of the three
groups. Animals were injected with TargMB-M126, Targ
MB-A126, or
TargMB-S126. All experiments involving animals were approved by
the Alfred Medical Research and Education Precinct Animal Ethics
Committee (E/1406/2013/B and E/1187/2012/B).
The animals were anesthetized using 1.5%–2% isoflurane. Breathing
of the animals was monitored to determine the amount of anesthetics
used. For animals undergoing ultrasound, the fur was removed by
shaving cream (Dove, Sydney, Australia). Mice were placed on a
37C heated mat to prevent hypothermia.
Acute Inflammatory Mouse Model
Male C57BL/6 mice, 6 to 7 weeks of age (20–25 g), were used for this
model. Animals were given an i.p. injection of 50 mg LPS diluted to
100 mL with PBS with calcium and magnesium. 18 hr post-injection,
the animals were anesthetized using 1.5%–2% isoflurane and placed
on the VisualSonics imaging station. The animals were assigned
www.moleculartherapy.orgrandomly to one of the three groups, and TargMB-M126, Targ
MB-A126,
or TargMB-S126 was injected via the tail vein. After 5 min of circula-
tion, we used the burst mode on the Vevo2100 high-frequency
small-animal ultrasound scanner and burst the MBs that were
attached on the thoracic and abdominal aorta. 48 hr post-ultrasound,
the abdominal aorta and the thoracic aorta of the animals were
removed for histology and qRT-PCR, respectively.
AAA Mouse Model
Male ApoE/ mice, 24 weeks of age, were used for this model. The
animals were anesthetized using 1.5%–2% isoflurane and placed on
a heated mat. A small incision was made in the skin between the scap-
ulae. The connective tissue was carefully spread to create a pocket for
an osmotic pump (model 2004, Alzet, Cupertino, CA). A pump
containing Ang-II (1,000 ng/kg/min, Sigma, St. Louis, MO) was
implanted subcutaneously on the back of the mouse, with the flow
mediator pointing away from the incision. The incision was closed us-
ing 6-0 fiber suture (Ethicon, Somerville, NJ). The animals were
checked extensively over the next 7 days. One week post-pump im-
plantation, the animals were assigned randomly to one of three groups,
and TargMB-M126, Targ
MB-A126, or Targ
MB-S126 was injected via the
tail vein. After 5 min of circulation, we used the burst mode on the
Vevo2100 high-frequency small-animal ultrasound scanner and burst
the MBs that were attached on the thoracic and abdominal aorta. The
injection of the respective treatments was repeated for week 2 andweek
3. At week 4, the abdominal aorta and the thoracic aorta of the animals
were removed for histology and qRT-PCR, respectively.
In Vivo Ultrasound Molecular Imaging
Ultrasound imaging was performed using a Vevo2100 small-animal
high-resolution imaging scanner (VisualSonics, Toronto, Canada)
using a 22- to 55-MHz high-frequency transducer (lateral resolution,
100 mm; transverse resolution, 40 mm; focal length, 10 mm; low
acoustic pressure or mechanical index, 0.14). The animals were anes-
thetized using 1.5%–2% isoflurane and placed on the imaging station.
Fur was removed by shaving with cream (Dove, Sydney, Australia).
For imaging of the abdominal aorta, the transducer was placed
directly over the abdomen of the mouse, with the transducer marker
facing 12 o’clock. All anatomical imaging was performed in funda-
mental brightness mode (B mode) using transmit power, 100%;
dynamic range, 65 dB.We ensured that the region of interest (abdom-
inal aorta and the branches of the renal arteries) was well visualized
via imaging. The diameter of the abdominal aorta was measured
both suprarenal (above the renal arteries) and infrarenal (below the
renal arteries). The position of the renal arteries ensures that the mea-
surements were repeatedly performed at the same area weekly and
therefore ensures its repeatability. For contrast imaging and ultra-
sonic burst, we used a 13- to 24-MHz high-frequency non-linear
contrast transducer. The animals were assigned randomly to one of
the three groups, and TargMB-M126, Targ
MB-A126, or Targ
MB-S126
was injected via the tail vein. Upon the injection of MBs, we imaged
using the nonlinear contrast mode (using transmit power, 10% and
dynamic range, 40 dB). After 5 min of circulation, we used the burst
mode on the Vevo2100 ultrasound scanner to burst theMBs that wereattached on the thoracic and abdominal aorta. When we employed
the burst mode to destroy the MBs, we use a continuous 10-MHz
high-power destructive pulse (using transmit power, 100%; high
mechanical index, 0.63; average power, 0.0676 W/cm2) applied
for 2 s every 10 s, which destroys the MBs within the beam elevation.
During the burst mode, the transducer is mechanically moved
to cover the desired target area. 15 cycles of burst were performed.
Videos and images were acquired throughout the imaging procedure.
Analysis was performed using VisualSonics imaging software
(VisualSonics, Toronto, Canada).
Immunohistochemistry
The abdominal aorta was harvested following 4 weeks of Ang-II
treatment or 3 days post-LPS injection, embedded in optimal cutting
temperature compound (OCT; Sakura Finetek, Torrance, CA) and
snapped frozen, and finally, 6-mm sections were obtained using a
cryostat (Microm HM525 NX, Thermo Fisher Scientific, Waltham,
MA). In order to determine VCAM-1 expression, multiple sections
per animal were selected at random and underwent immunostaining
using goat-anti-mouse VCAM-1 polyclonal antibody (Santa Cruz
Biotechnology, Dallas, TX) following acetone and formalin fixation
steps. The sections were then incubated with the appropriate bio-
tinylated secondary antibody (Vector Laboratories, Burlingame,
CA), and expression was determined via DDAB substrate (Vector
Laboratories, Burlingame, CA). All relevant controls were performed.
Sections of abdominal aorta were also stained for fibrin using MSB.
Thawed sections were treated with Weigert’s iron hematoxylin
(Sigma-Aldrich, MO), incubated with 96% ethanol, and stained
with Picric Orange G solution (EMS, PA). Sections were then further
stained with Brilliant Crystal Scarlet 6R (Sigma-Aldrich, St. Louis,
MO), and fibrin was differentiated using 1% phosphotungstic acid
(EMS, Hatfield, PA). Finally, sections were stained with Aniline
Blue solution (EMS, Hatfield, PA), rinsed in 1% acetic acid, dehy-
drated in 100% ethanol, cleared in xylene, and mounted using Depex
mounting medium (Labchem, Zelienople, PA). Sections were rinsed
in dH2O between each step. For this MSB trichrome stain, erythro-
cytes, fibrin, and collagen are represented by orange, bright red,
and blue, respectively. Sections were imaged using microscopy.
Microscopy
In vivo experiments were visualized with an IX81 Olympus micro-
scope (Olympus, Tokyo, Japan) and Cell^P 1692 (ANALYsis Image
Processing) software, using bright field with a 20 objective and
the tetramethylrhodamine (TRITC) fluorescence channel. Fluores-
cence was quantified using ImageJ software. Histological sections
were visualized with an Olympus BX050F-3 microscope (Olympus,
Tokyo, Japan) and CellSens software. All microscopy experiments
were performed at ambient temperature.
Statistical Analysis
Unless otherwise specified, data are expressed as mean ± SD.
Analyses containing 2 groups were analyzed with the Student’s
t test. All analyses containing more than two groups were analyzed
with one-way ANOVA with repeated measures (if equal numbers)Molecular Therapy Vol. 26 No 4 April 2018 1063
Molecular Therapyor ordinary (if unequal numbers), comparing all groups with one
another, corrected by post hoc Bonferroni analysis, and the
corrected p values are given. Statistical analyses were performed
using Graphpad Prism 6.0.
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